

Patient Report



Specimen ID: 068-996-9636-0
Control ID:

Acct #: 90000999
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

Phone: (336) 436-8645 Rte: 00

SAMPLE REPORT, 322777



Table with 3 columns: Patient Details, Specimen Details, Physician Details. Includes fields like DOB, Date collected, Date received, Date entered, Date reported, Ordering, Referring, ID, NPI.

General Comments & Additional Information

Clinical Info: NORMAL REPORT

Ordered Items

Renal Panel (10); Litholink CKD Program

Table with 7 columns: TESTS, RESULT, FLAG, UNITS, REFERENCE INTERVAL, LAB. Lists tests like Glucose, BUN, Creatinine, eGFR, Sodium, Potassium, Chloride, Carbon Dioxide, Calcium, Phosphorus, Albumin.

Litholink CKD Program

Interpretation Note 02

Medical Director's Note: Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results.

CHRONIC KIDNEY DISEASE:

EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
Estimated GFR is 60 mL/min/1.73mE2 or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Assessment of albuminuria (urine albumin:creatinine ratio or urine protein:creatinine ratio preferred) is recommended at least annually in CKD patients for staging and disease prognosis.

DISCLAIMER

Patient Report



Patient: SAMPLE REPORT, 322777

DOB: 01/10/1980

Patient ID:

Control ID:

Specimen ID: 068-996-9636-0

Date collected: 03/09/2022 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient. SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

PDF

02

01	RN	Labcorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
02	LITIL	Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	Dir: John Asplin, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-631-5250**

Accessions: 06899696360

DISCLAIMER: These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient.

SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

Note: Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.

Laboratory Director's Notes

Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.

COLLECTION DATE	ITEM	RELATED NOTES
03/09/2022		Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

John Asplin, MD - Laboratory Director

Chronic Kidney Disease

Analysis & Treatment Suggestions

GENDER	DIABETES	CURRENT eGFR	MOST RECENT CKD STAGE
M	?	115	

Prognosis of CKD by GFR And Albuminuria Categories

GFR Categories: (ml/min/1.73m ²)		A1	A2	A3
G1	>=90 NORMAL OR HIGH	Green	Yellow	Orange
G2	60-89 MILDLY DECREASED	Green	Yellow	Orange
G3a	45-59 MILDLY TO MODERATELY DECREASED	Yellow	Orange	Red
G3b	30-44 MODERATELY TO SEVERELY DECREASED	Orange	Red	Red
G4	15-29 SEVERELY DECREASED	Red	Red	Red
G5	<15 KIDNEY FAILURE	Red	Red	Red

Persistent Albuminuria Categories

A1 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g

A2 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g

A3 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g

Green = LOW RISK

Yellow = MODERATELY INCREASED RISK

Orange = HIGH RISK

Red = VERY HIGH RISK

● = PATIENT'S RESULT

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter.; Suppl.* 2013; 3: 1-150.

eGFR, Blood Pressure, and Proteinuria

Estimated GFR is 60 mL/min/1.73m² or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Treatment Suggestions

Assessment of albuminuria (urine albumin:creatinine ratio or urine protein:creatinine ratio preferred) is recommended at least annually in CKD patients for staging and disease prognosis.

Your Test Results



WITHIN GOAL



BORDERLINE



OUT OF GOAL

Test	Your Results	Comments
------	--------------	----------



Kidney Health

eGFR estimates how well your kidneys are filtering blood. The higher the number, the better your kidneys are working.

115

Ref Range: >59
mL/min/1.73mE2

YOUR RESULT SHOWS NORMAL KIDNEY FUNCTION. Control of diabetes and blood pressure can help to preserve kidney function.

DISCLAIMER: You should discuss this information with your physician. Labcorp does not have a doctor-patient relationship with you, nor does it have access to a complete medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range refers to the Labcorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES: National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at <http://kdigo.org>. Adapted from: https://www.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/Your_Kidney_Test_Results_EN.pdf.



Patient Report



Specimen ID: 068-996-9637-0
Control ID:

Acct #: 90000999
LabCorp Test Master
Test Account
5450 Millstream Road
MCLEANSVILLE NC 27301

Phone: (336) 436-8645

Rte: 00

SAMPLE REPORT, 322777



Table with 3 columns: Patient Details (DOB, Age, Gender, Patient ID), Specimen Details (Date collected, Date received, Date entered, Date reported), and Physician Details (Ordering, Referring, ID, NPI).

General Comments & Additional Information

Clinical Info: ABNORMAL REPORT

Ordered Items

Renal Panel (10); Litholink CKD Program

Table with 7 columns: TESTS, RESULT, FLAG, UNITS, REFERENCE INTERVAL, LAB. Rows include Glucose, BUN, Creatinine (1.50 High), eGFR, BUN/Creatinine Ratio, Sodium, Potassium, Chloride, Carbon Dioxide, Total, Calcium, Phosphorus (8.2 High), and Albumin.

Litholink CKD Program

Interpretation Note 02

Medical Director's Note: Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results.

CHRONIC KIDNEY DISEASE:

EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
Estimated GFR is 60 mL/min/1.73mE2 or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Assessment of albuminuria (urine albumin:creatinine ratio or urine protein:creatinine ratio preferred) is recommended at least annually in CKD patients for staging and disease prognosis.

DISCLAIMER

Patient Report



Patient: SAMPLE REPORT, 322777

DOB: 11/10/1985

Patient ID:

Control ID:

Specimen ID: 068-996-9637-0

Date collected: 03/09/2022 0000 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient. SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

PDF

02

01	RN	Labcorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
02	LITIL	Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	Dir: John Asplin, MD

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 800-631-5250**

Accessions: 06899696370

DISCLAIMER: These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to replace the physician's clinical judgment. They are derived from national guidelines in addition to other evidence and expert opinion. The clinician should consider this information within the context of clinical opinion and the individual patient.

SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at <http://kdigo.org/home/guidelines/>. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for children, pregnant patients, or transplant patients.

Note: Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.

Laboratory Director's Notes

Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.

COLLECTION DATE	ITEM	RELATED NOTES
03/09/2022		Effective 2/28/2022, Labcorp uses the 2021 CKD-EPI creatinine equation without a race factor to calculate and report eGFR results. eGFR results reported prior to this date using the 2009 CKD-EPI equation are no longer included in this report interpretation.

John Asplin, MD - Laboratory Director

Chronic Kidney Disease

Analysis & Treatment Suggestions

GENDER	DIABETES	CURRENT eGFR	MOST RECENT CKD STAGE
M	?	61	

Prognosis of CKD by GFR And Albuminuria Categories

GFR Categories: (ml/min/1.73m ²)		A1	A2	A3
G1	>=90 NORMAL OR HIGH	Green	Yellow	Orange
G2	60-89 MILDLY DECREASED	Green	Yellow	Orange
G3a	45-59 MILDLY TO MODERATELY DECREASED	Yellow	Orange	Red
G3b	30-44 MODERATELY TO SEVERELY DECREASED	Orange	Red	Red
G4	15-29 SEVERELY DECREASED	Red	Red	Red
G5	<15 KIDNEY FAILURE	Red	Red	Red

Persistent Albuminuria Categories

A1 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g

A2 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g

A3 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g

Green = LOW RISK

Yellow = MODERATELY INCREASED RISK

Orange = HIGH RISK

Red = VERY HIGH RISK

● = PATIENT'S RESULT

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter.; Suppl.* 2013; 3: 1-150.

eGFR, Blood Pressure, and Proteinuria

Estimated GFR is 60 mL/min/1.73m² or above; this patient is not presently in CKD stage 3 or higher, therefore we are unable to provide suggestions for treatment or follow-up.

Treatment Suggestions

Assessment of albuminuria (urine albumin:creatinine ratio or urine protein:creatinine ratio preferred) is recommended at least annually in CKD patients for staging and disease prognosis.

Your Test Results



WITHIN GOAL



BORDERLINE



OUT OF GOAL

Test	Your Results	Comments
------	--------------	----------



Kidney Health

eGFR estimates how well your kidneys are filtering blood. The higher the number, the better your kidneys are working.

61

Ref Range: >59
mL/min/1.73mE2

YOUR RESULT SHOWS MILDLY LOW KIDNEY FUNCTION. Control of diabetes and blood pressure can help to preserve kidney function.

DISCLAIMER: You should discuss this information with your physician. Labcorp does not have a doctor-patient relationship with you, nor does it have access to a complete medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range refers to the Labcorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES: National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at <http://kdigo.org>. Adapted from: https://www.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/Your_Kidney_Test_Results_EN.pdf.

